Trials / Completed
CompletedNCT01155713
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TKI258 |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2010-07-02
- Last updated
- 2020-12-21
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01155713. Inclusion in this directory is not an endorsement.